Galectin-1 (Gal1), an evolutionarily conserved glycan-binding protein, contributes to the creation of an immunosuppressed microenvironment at sites of tumor growth. In spite of considerable progress in elucidating its role in tumor-immune escape, the mechanisms underlying the inhibitory functions of Gal1 remain obscure. Here we investigated the contribution of tumor Gal1 to tumor growth, metastasis and immunosuppression in breast cancer. We found that the frequency of 
INTRODUCTION
The breast cancer microenvironment is composed of innate and adaptive immune components that actively influence the anti-tumor response (1) . The current view supports the idea that immune cells efficiently protect the host from arising tumors; however once a primary tumor is generated, the tumor-associated immune cell network can paradoxically promote tumor growth and metastasis (2) .
Lectin-glycan interactions have emerged as critical determinants of tumor progression (3).
Galectins, a family of endogenous lectins abundantly expressed in tumor microenvironments, can regulate transformation, angiogenesis, cell adhesion and tumor-immune escape (4-7). Galectin-1 (Gal1), a 'proto-type' member of this family, binds to multiple N-acetyllactosamine (Galβ1-4GlcNAc) units decorating complex N-and O-glycans on cell surface glycocoproteins (8) . Research from our laboratory has recognized an essential role for Gal1 as an immunoevasive mechanism in human and mouse melanoma (9) . These observations were further confirmed in mouse lung adenocarcinoma (10) (11) , and in human cancers including Hodgkin lymphoma (12) (13) , neuroblastoma (14) , head and neck squamous cell carcinoma (15) , pancreatic carcinoma (16), glioma (17) and T-cell lymphoma (18) , suggesting that targeting the Gal1-glycan axis might contribute to overcome immunosuppression and potentiate immunotherapeutic approaches.
Interestingly, Gal1 was identified as a tumor-associated protein capable of delineating the metastatic potential of human breast carcinoma (19) (20) . Importantly, stromal cell expression of Gal1 is up-regulated in invasive breast carcinoma as compared to in situ carcinoma, showing a positive correlation with T or TNM progression stages (21) .
Extracellularly, Gal1 acts by cross-linking glycosylated receptors on the surface of immune cells and modulating their survival, cytokine production and trafficking (3, (22) (23) (24) (25) . This glycan- Author Manuscript Published OnlineFirst on ; DOI: 10.1158/0008-5472. CAN-12-2418 profile (9, 23) , by selectively deleting Th1 and Th17 cells (22) and by promoting the differentiation of tolerogenic dendritic cells (DCs) (11, 14, 26) . Moreover, Gal1 facilitates the expansion of IL-10-producing T regulatory type-1 (Tr1) cells (23, (26) (27) 
FoxP3
+ T regulatory (T reg ) cells (28) (29) .
With the ultimate goal of validating the Gal1-glycan axis as a novel therapeutic target, in the present study we examined the contribution of Gal1 to breast cancer-induced immunosuppression, tumor growth and metastasis. We used the highly metastatic mouse mammary tumor model 4T1, which recapitulates several features of advanced human breast cancer including lack of hormone receptors and the ability to generate spontaneous lung and lymph nodes metastasis (30 
MATERIALS AND METHODS

Mice and Human Samples
Female BALB/c mice or C57BL/6 (8-12 weeks) were housed at the animal facility of the Institute of Biology and Experimental Medicine (IBYME) according to NIH guidelines. Formalin-fixed, paraffinembedded tumor sections were obtained from the Department of Pathology, Centro Hospitalario Pereira Rossell, Montevideo, Uruguay. Protocols were approved by the Institutional Review Board of IBYME.
Immunohistochemistry
Paraffin-embedded tissues were sectioned at 4 μm and mounted. After deparaffinization, tissues were stained with rabbit anti-Gal1 antibody (Ab) (9) (1:500 or 1:400 for human or mouse respectively) or anti-Foxp3 (e-Bioscience; 1:100) and revealed using the Vectastain Elite ABC kit (Vector). Staining was scored as: 0 (negative), 1 (0-30% positive), 2 (30-60% positive) or 3 (more than 60% positive) and classified as weak (0-1) or strong (2-3).
Cells and knockdown (KD) clones
4T1 and B16 cells were acquired from the American Type Culture Collection (ATCC) and were maintained in DMEM 10% FCS (Gibco). Three Gal1-specific and one scramble shRNAs were cloned into the pSIREN-RetroQ vector (12) . Viral production was performed using RetroPack PT-67 packaging cell line (BD Clontech) according to manufacturer´s instructions. 4T1 cells were infected using viral supernatants plus 8 µg/ml polybrene. Clones were selected with puromycin (5 μg/ml) by limited dilution. 
Immunoblotting
In vitro proliferation assays
In vitro tumor cell growth was measured by the MTS assay (9) using an in house-made ELISA as described (32) . RNA was obtained using TRIZOL reagent following manufacturer's instructions. DNA contamination was removed using DNAse I. cDNA was synthesized using Super Scrip III Reverse Transcriptase (Invitrogen). For real time, the SYBR Green PCR Master Mix was used with an ABI System 7500 (Applied Biosystem). Primers: Gal1 5'-TCAGCCTGGTCAAAGGTGAT-3' 5'-
Real-time PCR
A commercial kit was used to screen mouse genes implicated in T cell anergy and tolerance RT2 Profiler PCR array (PAMM-074, SA Biosciences). Screening of the 84 pathway-specific genes was performed in duplicate (n=4).
Statistical analysis
Prism software (GraphPad) was used. Two groups were compared with the Student´s-t test for 
RESULTS
Expression of Gal1 correlates with the aggressiveness of human breast tumors and is upregulated in the mouse metastatic 4T1 breast cancer model
We first examined the expression of Gal1 in human breast carcinoma tissues.
Immunohistochemical analysis of a collection of human breast adenocarcinomas (n=55 patients) revealed expression of Gal1 in both epithelial and stromal cells ( Figure 1A 
Knocking down Gal1 in breast cancer decreases tumor burden and prevents lung metastasis
To study the role of Gal1 in breast cancer, we knocked down Gal1 in 4T1 cells by transduction with a retroviral vector containing a mouse Gal1-specific shRNA sequence (4T1-KD). 
Targeted disruption of Gal1 eliminates tumor-mediated immunosuppression in vivo
To further dissect the mechanisms underlying the pro-tumoral effects of Gal1, we examined whether expression of this lectin in the tumor microenvironment influences systemic immunosuppression. We hypothesized that if a Gal1-deficient tumor is inoculated simultaneously with a Gal1-sufficient tumor in the contralateral side, tumor-derived Gal1 will provide the tolerogenic milieu necessary to systemically blunt effector T cell responses. As a result, the Gal1 KD tumor will behave as a WT tumor in terms of promotion of tumor growth and metastasis. 
was similar to that observed in the WT/WT group and was considerably enhanced when compared to the KD/KD group ( Figure 4B) . Remarkably, splenocytes from mice bearing WT/WT or WT/KD tumors failed to proliferate ex vivo in response to tumor antigens while splenocytes isolated from KD/KD tumors showed robust proliferation in response to 4T1 cell lysates ( Figure 4C) . Notably, the frequency of T reg cells present within the Gal1 KD TDLN was as elevated as the WT TDLN ( Figure   4D ). Collectively, these results indicate that the presence of a WT tumor promotes a dominant systemic immunosuppression that thwarts the development of an effective anti-tumor response.
Previous studies showed that mice inoculated with 4T1 tumors exhibit impaired rejection of allogeneic tumors, suggesting a compromised effector T-cell function (35) . We examined Previous studies indicated that breast cancer-derived Gal1 could control tumor progression (21, (40) (41) . Using the mouse mammary adenocarcinoma LM3 and the human breast tumor line MCF-7, we previously found that Gal1 is under the control of TGF-β, suggesting that both mediators might act in concert to counteract antitumor responses (42) . Importantly, in samples of human breast carcinoma tissues, higher Gal1 expression was observed in stromal cells of invasive compared to in situ carcinomas (21) . The authors found that Gal1 expression in the tumor stroma positively correlated with T and TNM stages in a selected cohort of breast cancer patients (21) . Moreover, Gal1 was identified as an abundant protein in the tumor interstitial fluid in breast cancer tissues as compared to normal interstitial fluid (43) , suggesting that tumorsecreted Gal1 could serve as a potential biomarker for early detection of the disease.
Research over the past few years has revealed novel insights into the mechanisms underlying the immunoregulatory functions of Gal1. We previously found that Gal1-glycan interactions negatively regulate the survival of effector Th1 and Th17 cells (22) . As Th1 and Th17 
